). The additional verification step was introduced to ensure laboratories had all the documentation and permits in place that were required to import the material into their country.
| Panel description
The proficiency testing (PT) panel consisted of 11 specimens. This was made up of nine specimens (A to I) of inactivated (gamma irradiation; 50 kGy) MERS-CoV, human coronavirus OC43, human coronavirus 229E, and a negative control (specimen I), as well as two synthetic specimens (J and K) containing in vitro RNA transcripts.
RCPAQAP have used similar transcripts in previous PT panels, and have shown that they are safe, stable, and reliable. 8 The design of that would yield an equivocal result, as confirmatory testing to initial screening would return negative.
All specimens provided were lyophilized and tested for homogeneity and stability. Homogeneity was confirmed, and no significant sample degradation was detected after storage for 7 days at 37°C Following gamma irradiation of the viruses, inactivation was confirmed and viral RNA was quantified using real-time PCR. 8 The relative measure of the concentration of virus-specific target was determined by generating standard curves using a set of MERSCoV-specific and HCoV-specific primers to quantify the genome equivalents (GE) copies per millilitre of each specimen. 6, 7 Three external referee laboratories confirmed sample characteristics.
| Assessment criteria
Participants were requested to test all specimens of the PT panel and specimens is presented in Table 3 .
| Limit of detection for MERS-CoV-specific PCR
The PT panel included a 10-fold dilution series (specimens D, E, F, and G), covering MERS-CoV RNA concentrations ranging from (Table 3 ).
| Synthetic specimens
Eighty-one of ninety-six (84.4%) laboratories confirmed the presence of MERS-CoV in specimen J, which contained all five in-vitro RNA transcripts. For this specimen, seven (7.3%) laboratories ruled out the presence of MERS-CoV and eight (8.3%) participants did not specify.
Specimen K contained one in-vitro RNA transcript, for which 49 of 96 (51.0%) laboratories reported the presence of MERS-CoV. Twentyeight (29.2%) and 19 (19.8%) participants ruled out or did not specify the presence of MERS-CoV, respectively (Table 3) .
| Methods used for the detection of MERS-CoV
All 96 participating laboratories tested the specimens of the PT panel for the presence or absence of MERS-CoV. The gene targets used by participants to confirm or rule out the presence of MERS-CoV in each of the 11 specimens were upE, ORF1a, ORF1b, N, and RdRp (Table 4) . Qiagen, Macherey-Nagel, and Roche were used by seven, five, and four participants, respectively.
| DISCUSSION
The PTP provides insight into the diagnostic methodology and performance of laboratories in detecting MERS-CoV worldwide.
The high level of concordance between the 96 participating laboratories suggests a high global capacity to detect MERS-CoV. MERS-CoV at lower concentrations. This finding is similar to that of two previous external quality assessments, which reported some laboratories to have reduced assay sensitivity when assessed on a 10-fold MERS-CoV dilution panel. 11, 12 These studies also demonstrated a high overall capacity for laboratories to detect MERS-CoV in China, 11 and worldwide. 12 Similarly, a study performed during the 2015 Korean outbreak reported a 100% MERS-CoV detection score amongst 47 participants. 13 However, the panel in this study only consisted of three specimens, limiting their assessment of assay sensitivity. Both the Korean and Chinese external quality assessments differed from this PTP in that they did not include other human coronaviruses for the assessment of assay specificity. Access to and participation in future quality assurance (QA) programs will provide the opportunity for improvement at a technical level.
Offering an ongoing PTP for the detection of MERS-CoV and other human coronaviruses by PCR will ensure that this capacity will remain appropriate and provide continuing opportunities for improvement.
Results for the detection and identification of other human coronaviruses were less conclusive, with just 28.1% and 30.2% of laboratories scoring correctly in all samples, respectively. However these results were unsurprising, as a large proportion of participants 
